ONC
The table below shows BeOne Medicines AG's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B | $308.87M |
| Cost of revenue | - | - | - | $286.48M | $164.91M | $70.66M |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B | - |
| R&D | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B | $1.29B |
BeOne Medicines AG reported annual revenue of $5.34B for fiscal year 2025. That is up 40.2% from $3.81B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.07M (FY 2016) to $5.34B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.08B |
| $1.83B |
| $1.51B |
| $1.28B |
| $990.12M |
| $600.18M |
| Operating income | $447.14M | -$568.20M | -$1.21B | -$1.79B | -$1.44B | -$1.66B |
| Income tax | $129.92M | $111.78M | $55.87M | $42.78M | $19.23M | $10.40M |
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | -$1.46B | -$1.62B |
| EPS (diluted) | $0.19 | -$0.47 | -$0.65 | -$1.49 | -$1.21 | -$1.50 |